uniQure (QURE) Earnings Date & Reports

Key Takeaways

• uniQure reported third quarter 2026 revenue of $5.2 million, up from $3.7 million a year earlier but below consensus estimates.
• The company posted a net loss of $61.2 million, or $0.88 per share, narrowing from a loss of $1.38 per share in the prior-year period.
• The U.S. Food and Drug Administration (FDA) accepted the Biologics License Application (BLA) for AMT-130 and granted Priority Review with a target action date of May 1, 2027.
• Cash, cash equivalents, and investment securities totaled $768.4 million as of September 30, 2026, which management expects will fund operations into 2030.
• Research and development (R&D) expenses rose to $35.5 million, while selling, general, and administrative (SG&A) expenses climbed to $23.9 million as the company prepares for a potential commercial launch.
• For more detail on this ticker, explore its Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages.
• To discover actionable market signals, consider exploring Trending AI Robots.

Earnings Context and Why It Matters

uniQure's quarterly financials are closely watched less for their headline figures and more for the regulatory progress of its lead gene therapy candidate, AMT-130. As a clinical-stage biotechnology company with limited product revenue, the company's investment thesis hinges on the path toward the first potential disease-modifying treatment for Huntington's disease. This quarter arrived with that narrative front and center: the FDA accepted the company's BLA under the Accelerated Approval pathway and granted Priority Review. For investors, the report serves as a checkpoint on both the financial runway needed to reach commercialization and the execution risks tied to regulatory review and launch readiness.

Reported Results

For the third quarter ended September 30, 2026, uniQure reported revenue of $5.2 million, an increase from $3.7 million in the same period of 2025, driven by higher license revenue. The figure came in below analyst consensus estimates, which had ranged around $6 million to $7 million. The net loss for the quarter was $61.2 million, or $0.88 per basic and diluted share, an improvement from a net loss of $80.5 million, or $1.38 per share, a year earlier.

R&D expenses were $35.5 million, up from $34.4 million, while SG&A expenses increased to $23.9 million from $19.4 million, reflecting headcount growth and information technology costs tied to potential commercial launches. The company ended the quarter with $768.4 million in cash, cash equivalents, and investment securities, up from $622.5 million at the end of 2025. Management reaffirmed that this balance is expected to fund operations into 2030.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. If you are looking to complement your fundamental research with data-driven discovery, the AI Screener can help streamline that process.

Market Reaction and Investor Sentiment

Sentiment around uniQure's report has been shaped more by the regulatory milestone than by the income statement. The FDA's acceptance of the AMT-130 BLA under Priority Review, alongside validation of the U.K. marketing application by the Medicines and Healthcare products Regulatory Agency (MHRA), reinforces the thesis that the company is advancing toward a potential approval decision. At the same time, the stock has experienced volatility in recent months, reflecting uncertainty over the regulatory path, including the FDA's tentative plan to convene an advisory committee and questions about whether the confirmatory study will be sufficiently underway by the Prescription Drug User Fee Act (PDUFA) action date of May 1, 2027.

Forward Outlook and Key Factors to Monitor

The central catalyst for uniQure is the FDA's review of AMT-130, with a PDUFA target action date of May 1, 2027. Investors will closely watch whether the agency schedules an advisory committee meeting and whether any information requests could push back the timeline. Management has noted that a request for additional longer-term data could be treated as a major amendment and delay the action date.

The confirmatory study represents another key execution priority. uniQure has aligned with the FDA on a randomized trial enrolling approximately 200 patients, comparing AMT-130 against standard of care with Total Functional Capacity (TFC) as the primary endpoint. The company expects to begin patient screening in the United States by the end of 2026, and progress on enrollment will be a closely monitored signal.

Beyond the Huntington's disease program, investors should track pipeline updates. uniQure has completed enrollment in the second dose cohort of its AMT-260 study in refractory temporal lobe epilepsy and has resumed enrollment in the AMT-191 study for Fabry disease, with updated data expected in the first half of 2027. Commercial readiness, including the number of treatment centers activated and early payer engagement, will also shape how the market interprets the company's path toward a potential launch.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations